Amneal Pharmaceuticals (NASDAQ: AMRX) revenue
Amneal Pharmaceuticals reported revenue of $3,019m for fiscal 2025, 8.0% more than in fiscal 2024 ($2,794m). Since fiscal 2017 its revenue has grown by 192.0%, an average growth of 14.3% a year.
Amneal Pharmaceuticals has grown its revenue for 6 years in a row, and fiscal 2025 is the highest of its 9 fiscal years on record. The biggest drop was in fiscal 2019, −2.2%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $3,019m | +8.0% | $394.1m | 13.1% |
| 2024 | $2,794m | +16.7% | $249.3m | 8.9% |
| 2023 | $2,394m | +8.2% | $204.4m | 8.5% |
| 2022 | $2,212m | +5.7% | −$94.9m | −4.3% |
| 2021 | $2,094m | +5.1% | $152.7m | 7.3% |
| 2020 | $1,993m | +22.5% | $91.2m | 4.6% |
| 2019 | $1,626m | −2.2% | −$248.7m | −15.3% |
| 2018 | $1,663m | +60.9% | −$19.7m | −1.2% |
| 2017 | $1,034m | — | $245.1m | 23.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Amneal Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Amneal Pharmaceuticals ranks 89th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Amneal Pharmaceuticals, 8.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 87th | Waters | $3,165m | 7.0% |
| 88th | West Pharmaceutical Services | $3,074m | 6.3% |
| 89th | Amneal Pharmaceuticals | $3,019m | 8.0% |
| 90th | Globus Medical | $2,939m | 16.7% |
| 91st | Neurocrine Biosciences | $2,861m | 21.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Amneal Pharmaceuticals
- How much revenue did Amneal Pharmaceuticals make in fiscal 2025?
- Amneal Pharmaceuticals reported revenue of $3,019m for fiscal 2025, compared with $2,794m in fiscal 2024.
- How much has the revenue of Amneal Pharmaceuticals grown?
- Between fiscal 2017 and fiscal 2025 it went from $1,034m to $3,019m: 192.0% more, an average growth of 14.3% a year.
- What was the best year for revenue at Amneal Pharmaceuticals?
- Of its last 9 fiscal years, fiscal 2025, with $3,019m.
- Where does Amneal Pharmaceuticals rank in its sector by revenue?
- It ranks 89th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Amneal Pharmaceuticals come from?
- From the annual report (Form 10-K) that Amneal Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Amneal Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Amneal Pharmaceuticals: the Amneal Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.